Patent ID: 8754078
Filing Date: 2014-06-17
Classification: A61K,A61P,C07D,C07F,C07K

Abstract:
1. A pharmaceutical composition comprising a first chemotherapeutic agent including a pyrroloquinolinyl-pyrrolidine-2,5-dione compound of formula IVa, IVb, Va, or Vb, or pharmaceutically acceptable salts thereof: where: R1, R2 and R3 are independently selected from the group consisting of hydrogen, F, Cl, Br, I, —NR5R6, —(C R4 is independently selected from the group consisting of hydrogen, —(C R5, R6 are independently selected from the group consisting of hydrogen, and —(C R7 is independently selected from the group consisting of —O—P(═O)(OH) Q is selected from the group consisting of aryl, heteroaryl, —O-aryl, —S-aryl, —O-heteroaryl, and —S-heteroaryl; wherein said aryl, heteroaryl, —O-aryl, —S-aryl, —O-heteroaryl, and —S-heteroaryl groups may be substituted with one or more substituents independently selected from the group consisting of F, Cl, Br, I, —NR5R6, —(C further comprising an effective amount of a second chemotherapeutic agent selected from the group consisting of tamoxifen, raloxifene, anastrozole, exemestane, letrozole, trastuzumab, imatinib, paclitaxel, cyclophosphamide, lovastatin, mimosine, gemcitabine, araC, 5-fluorouracil, methotrexate, docetaxel, goserelin, vincristine, vinblastine, nocodazole, teniposide, etoposide, epothilone, navelbine, camptothecin, daunorubicin, dactinomycin, mitoxantrone, amsacrine, doxorubicin, epirubicin and idarubicin.